Concordia Healthcare Corp. to Host Fourth Quarter and Year-end 2014 Results Conference Call

TORONTO, March 16, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its fourth quarter and year-end 2014 financial results after market close on Thursday, March 19, 2015.

The Company will subsequently hold a conference call on Friday, March 20, 2015, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com or by going to http://www.newswire.ca/en/webcast/detail/1499535/1670573

An archived replay of the webcast will be available for one year.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs.   Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of the following products: ADHD-treatment Kapvay® (clonidine extended release tablets), head lice treatment Ulesfia® (benzyl alcohol) Lotion, asthma-related medication Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets), irritable bowel syndrome treatment Donnatal® (belladonna alkaloids, phenobarbital) and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia's specialty healthcare distribution (SHD) division, Complete Medical Homecare, distributes medical supplies targeting diabetes and related conditions. Concordia's orphan drugs division, Concordia Laboratories Inc., manufactures PHOTOFRIN®. PHOTOFRIN® is marketed by Pinnacle Biologics, Inc. in the United States.

Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Kansas City, Missouri; Chicago, Illinois and Charlottesville, Virginia.

SOURCE Concordia Healthcare Corp.